What is Y-Trap?
Y-Trap is at the forefront of next-generation cancer immunotherapy, specializing in the development of innovative multispecific antibodies. Their proprietary technology is designed to reprogram the tumor immune microenvironment, effectively counteracting the immunosuppressive phenotypes that allow tumors to evade immune system detection. The company's focus on unique therapeutic approaches aims to significantly advance cancer treatment options for patients.
How much funding has Y-Trap raised?
Y-Trap has raised a total of $93K across 1 funding round:
Debt
$93K
Debt (2021): $93K with participation from PPP
What's next for Y-Trap?
With the recent influx of substantial expansion capital, Y-Trap is strategically positioned for significant growth and scaling. This investment will likely fuel further research and development, accelerate clinical trials, and potentially expand the company's operational capacity. The Series B/C stage funding indicates a transition towards broader market penetration and the commercialization of their advanced cancer treatment solutions.
See full Y-Trap company page